1. 2022
  2. Molecular characterization of colorectal cancer related peritoneal metastatic disease

    Lenos, K. J., Bach, S., Ferreira Moreno, L., ten Hoorn, S., Sluiter, N. R., Bootsma, S., Vieira Braga, F. A., Nijman, L. E., van den Bosch, T., Miedema, D. M., van Dijk, E., Ylstra, B., Kulicke, R., Davis, F. P., Stransky, N., Smolen, G. A., Coebergh van den Braak, R. R. J., IJzermans, J. N. M., Martens, J. W. M., Hallam, S., & 20 othersBeggs, A. D., Kops, G. J. P. L., Lansu, N., Bastiaenen, V. P., Klaver, C. E. L., Lecca, M. C., el Makrini, K., Elbers, C. C., Dings, M. P. G., van Noesel, C. J. M., Kranenburg, O., Medema, J. P., Koster, J., Koens, L., Punt, C. J. A., Tanis, P. J., de Hingh, I. H., Bijlsma, M. F., Tuynman, J. B. & Vermeulen, L., 1 Dec 2022, In: Nature communications. 13, 1, 4443.

    Research output: Contribution to journalArticleAcademicpeer-review

  3. Serum-based measurements of stromal activation through ADAM12 associate with poor prognosis in colorectal cancer

    ten Hoorn, S., Waasdorp, C., van Oijen, M. G. H., Damhofer, H., Trinh, A., Zhao, L., Smits, L. J. H., Bootsma, S., van Pelt, G. W., Mesker, W. E., Mol, L., Goey, K. K. H., Koopman, M., Medema, J. P., Tuynman, J. B., Zlobec, I., Punt, C. J. A., Vermeulen, L. & Bijlsma, M. F., 1 Dec 2022, In: BMC cancer. 22, 1, 394.

    Research output: Contribution to journalArticleAcademicpeer-review

  4. Estrogen-related receptor alpha drives mitochondrial biogenesis and resistance to neoadjuvant chemoradiation in esophageal cancer

    Dings, M. P. G., van der Zalm, A. P., Bootsma, S., van Maanen, T. F. J., Waasdorp, C., van den Ende, T., Liu, D., Bailey, P., Koster, J., Zwijnenburg, D. A., Spek, C. A., Klomp, J. P. G., Oubrie, A., Hooijer, G. K. J., Meijer, S. L., van Berge Henegouwen, M. I., Hulshof, M. C., Bergman, J., Oyarce, C., Medema, J. P., & 2 othersvan Laarhoven, H. W. M. & Bijlsma, M. F., 15 Nov 2022, In: Cell Reports Medicine. 3, 11, 100802.

    Research output: Contribution to journalArticleAcademicpeer-review

  5. The contributions of hypoxia to poor outcomes in pancreatic cancer

    Bijlsma, M. F., 1 Nov 2022, In: TRANSLATIONAL CANCER RESEARCH. 11, 11, p. 3935-3937

    Research output: Contribution to journalEditorialAcademicpeer-review

  6. C/EBPδ Suppresses Motility-Associated Gene Signatures and Reduces PDAC Cell Migration

    Hartl, L., Maarschalkerweerd, P. A. F., Butler, J. M., Manz, X. D., Thijssen, V. L. J. L., Bijlsma, M. F., Duitman, J. & Spek, C. A., Nov 2022, In: Cells. 11, 21, 3334.

    Research output: Contribution to journalArticleAcademicpeer-review

  7. Impact of classical and basal-like molecular subtypes on overall survival in resected pancreatic cancer in the SPACIOUS-2 multicentre study

    Dutch Pancreatic Cancer Group, 14 Oct 2022, In: The British journal of surgery. 109, 11, p. 1150-1155 6 p.

    Research output: Contribution to journalArticleAcademicpeer-review

  8. Resistance mechanisms to HER2-targeted therapy in gastroesophageal adenocarcinoma: A systematic review

    Blangé, D., Stroes, C. I., Derks, S., Bijlsma, M. F. & van Laarhoven, H. W. M., 1 Jul 2022, In: Cancer treatment reviews. 108, 102418.

    Research output: Contribution to journalReview articleAcademicpeer-review

  9. Editorial: Translational Insights Into Pancreatic Ductal Adenocarcinoma

    Bijlsma, M. F., Bailey, P. J. & Stemmler, M. P., 1 Apr 2022, In: Frontiers in cell and developmental biology. 10, 875836.

    Research output: Contribution to journalEditorialAcademicpeer-review

  10. Mesoporous Silica Nanoparticle-Based Drug Delivery Systems for the Treatment of Pancreatic Cancer: A Systematic Literature Overview

    Slapak, E. J., el Mandili, M., Bijlsma, M. F. & Spek, C. A., 1 Feb 2022, In: Pharmaceutics. 14, 2, 390.

    Research output: Contribution to journalReview articleAcademicpeer-review

Previous 1 2 3 4 5 6 7 8 ...14 Next

ID: 41996